(R) -Levrazoxane

(R) -Levrazoxane ((R) -ICRF 186) is enzymatically hydrolysed to one-ring open intermediates by dihydropyrimidine amidohydrolase (DPHase), which is present in the liver and kidney. The radiosensitizing efficiency of (R) -Levrazoxane towards EMT6 mouse mammary tumour cells is greater than that of Dexrazoxane (HY-B0581) . (R) -Levrazoxane is promising for research of liver and kidney related diseases[1].

Product Specifications

CAS Number

[24613-06-7]

Product Name Alternative

(R) -ICRF 186

UNSPSC

12352005

Hazard Statement

H302+H312+H332-H315-H319

Target

Drug Intermediate

Type

Reference compound

Related Pathways

Others

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/r-levrazoxane.html

Smiles

C[C@H](CN(CC(N1)=O)CC1=O)N(CC(N2)=O)CC2=O

Molecular Formula

C11H16N4O4

Molecular Weight

268.27

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P501

References & Citations

[1]Hasinoff BB, et al. Metabolism of the cardioprotective agents dexrazoxane (ICRF-187) and levrazoxane (ICRF-186) by the isolated hepatocyte. Xenobiotica. 1994 Oct;24 (10) :977-87.